Lumito invites to a webinar in connection with the publication of its third-quarter 2026 report
On Thursday, 29 October 2026, Lumito AB (publ) ("Lumito" or the "Company") will publish its report for the third quarter of 2026. In connection with the publication, shareholders, investors and other interested parties are invited to a webinar on Friday, 30 October at 8:30 a.m. CET. During the presentation, Sanna Wallenborg, CEO, will provide a […]
Lumito’s SCIZYS® demonstrates an approximately tenfold wider PSA measurement range in a pilot study with a leading prostate cancer researcher
Lumito AB (publ) ("Lumito" or the "Company") announces today that the first part of the pilot project with Anders Bjartell, Professor of Urology at Lund University and a leading prostate cancer researcher, has been completed with very positive results. The study, conducted on lymph node samples from patients with prostate cancer, shows that Lumito’s SCIZYS® […]
Lumito strengthens its commercial position through partnership with Aurevia in advanced tissue analysis
Lumito AB (publ) ("Lumito" or the "Company") has entered into a collaboration with Aurevia AB ("Aurevia"), a CRO company specialising in clinical research and regulatory services. Through the collaboration, Lumito gains access to an additional established channel for reaching potential customers in drug development and clinical research. At the same time, Aurevia can broaden its […]
Lumito and Navinci put further collaboration on hold following promising pilot results
Lumito AB (publ) (”Lumito” or the ”Company”) has completed the pilot study with Navinci Diagnostics AB (”Navinci”) that was initiated in July 2026. The pilot study has shown promising results that strengthen Lumito’s work to verify the functionality of SCIZYS® and create conditions for increased sales. However, due to changed priorities at Navinci, the results […]
Lumito publishes investor letter
Lumito AB (publ) (”Lumito” or the ”Company”) today publishes an investor letter where the Company, among other things, follows up on the objectives that were announced in connection with the rights issue during the summer. ”We have taken clear steps forward in the commercialisation of SCIZYS. Through more qualified customer and partner discussions, progress in […]
Lumito demonstrates successful integration of SCIZYS® within automated laboratory workflow
Lumito AB (publ) ("Lumito" or the "Company") announces the successful integration of the Company's SCIZYS® Erbium kit with the automated laboratory platform for staining tissue samples from CliniSciences S.A.S (“CliniSciences”). The tests were conducted at CliniSciences using Lumito's SCIZYS® Erbium kit and produced high-quality images without prior protocol optimisation. The integration represents an important milestone […]
External study demonstrates new application areas for SCIZYS® in immunological research
Lumito AB (publ) (“Lumito” or the “Company”) highlights a recently published, peer-reviewed scientific study in which SCIZYS® has been used to analyse biomarkers in immune cells within a new research area. The study demonstrates an application of SCIZYS® in cell-based research and complements previous scientific documentation, where tissue samples have been the primary focus. The […]
Lumito receives first order outside the Nordic region
Lumito AB (publ) (“Lumito” or the “Company”) has received an order from a European university hospital. The order, valued at approximately EUR 4,000, is the Company’s first order outside the Nordic region since its commercial launch and thus marks an initial commercial step into a new geographical market. The order includes a SCIZYS Erbium Kit […]
Lumito terminates mentorship agreement
Lumito AB (publ) (“Lumito” or the “Company”) has terminated its mentorship agreement with Mangold Fondkommission AB. Under the rules of NGM Nordic SME, the obligation to appoint a mentor applies during the first two years following a listing. Lumito has been listed since autumn 2018 and considers that the mentorship is no longer necessary. The […]
Lumito publishes interim report for the second quarter of 2026
Financial overview Second quarter 2026, April 1 – June 30Net sales amounted to SEK 0 thousand (0).Profit/loss after tax amounted to SEK -10,059 thousand (-11,275).Earnings per share before and after dilution amounted to SEK -2.04 (-0.04).Cash flow from operating activities after changes in working capital amounted to SEK -4,159 thousand (-7,374). First half of 2026, […]